Epirubicin
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Northwestern UniversityPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Nodal Peripheral T-Cell Lymphoma With TFH Phenotype cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pralatrexate Corvus Pharmaceuticals, Inc. | Phase 3 | BB |
Cyclophosphamide City of Hope Medical Center | Phase 2 | BB |
Pembrolizumab Northwestern University | Phase 2 | B |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →